MacroGenics (MGNX) to Release Quarterly Earnings on Thursday

MacroGenics (NASDAQ:MGNX - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.61) per share and revenue of $9.59 million for the quarter.

MacroGenics (NASDAQ:MGNX - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%. The firm had revenue of $49.40 million for the quarter, compared to the consensus estimate of $34.17 million. On average, analysts expect MacroGenics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MacroGenics Trading Up 4.2 %

Shares of MGNX traded up $0.07 during mid-day trading on Friday, hitting $1.75. 660,525 shares of the company traded hands, compared to its average volume of 1,134,557. MacroGenics has a one year low of $0.99 and a one year high of $16.44. The stock has a market capitalization of $110.41 million, a price-to-earnings ratio of -1.11 and a beta of 2.23. The business has a 50-day moving average of $1.72 and a 200 day moving average of $2.76.

Wall Street Analyst Weigh In

Several research firms have weighed in on MGNX. StockNews.com lowered MacroGenics from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. HC Wainwright decreased their price target on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, March 25th. Nine research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $7.38.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.